Kornimate/medical-research-clean huggingface dataset:
drug repurposing - statins as microbiota modulating agents in ulcerative colitis

Conditions: Ulcerative Colitis

Summary: * evaluation of the microbiota modulation away from inflammation associated microbiota profile bacteroides2 (bact2) * evaluation of the microbiota modulation potential of statins in bact2- enterotyped, healthy volunteers and ulcerative colitis patients. * evaluation of the effect of microbiota modulation on disease activity in ulcerative colitis patients. * evaluation of reduced inflammatory parameters of participants involved in trial


Eligibility criteria:
inclusion criteria: * general criteria * bact2 enterotyped one month before start of study intervention (at least 150 of enrolled participants must meet this criteria) * willingness to participate in the study and to sign the informed consent (dutch) * between 18 and 70 years old * access to a -20°c freezer criteria specific to uc patients * patients in remission (mayo score below 4) or with currently mild to moderate active ulcerative colitis (defined by mayo score of 4-10), despite stable medication (8 weeks) and a mayo endoscopic sub-score 2- 3 at week 0 criteria specific to healthy bact2 participants * individuals with no physician diagnosed diseases or disorders exclusion criteria: * general criteria * prior and/or ongoing use of statins before study start * history of surgical intervention in gastrointestinal tract (appendectomies are allowed) * females who are pregnant or actively trying to become pregnant * individuals with active liver disease including unexplained persistent elevations of serum transaminases and any serum transaminases elevation exceeding three times the upper limit of normal (uln) * lactose intolerance * pre-diabetic participants * personal or family history of hereditary muscular disorders * individuals with a history of or diagnosed with alcohol abuse criteria specific to uc patients * other conditions leading to profound immunosuppression such as hiv, infectious diseases leading to immunosuppression, bone marrow malignancies, liver cirrhosis * a diagnosis of crohn's disease or indeterminate colitis * individuals with hypothyroidism * individuals with a diagnosis of diabetes mellitus * individuals with severe renal impairment (creatinine clearance \<30 ml/min) * individuals with myopathy * participants who have taken antibiotics sometime in the past four months * use of antibiotics one month prior to week 0 * steroid dependency and requiring \>16mg medrol (methyl prednisone) or equivalent two week before week 0 criteria specific to healthy bact2 participants * participants with family history of autoimmune chronic inflammatory diseases like multiple sclerosis, ibd, and rheumatoid arthritis

Keywords: microbiome dysbiosis
health coach program to improve chronic disease outcomes following an emergency department visit

Conditions: Diabetes Mellitus; Hypertension

Summary: the purpose of this study is to determine whether health coaching initiated in the emergency department (ed) reduces subsequent ed visits, increases primary care visits, and positively impacts health outcomes in patients with diabetes and/or hypertension.

patients will be recruited by health coaches from the highland hospital emergency department. eligible patients who agree to participate will be randomized to the control and experimental groups in a 2:1 ratio respectively because experimental group size is limited by health coach availability and greater loss-to-follow up is expected among the control group. repeated measures analysis will be used to compare each outcome over the study period. in addition, subgroup analyses will be performed in order to stratify by baseline survey measures or amount of ed visits in the pre-observation period.

Eligibility criteria:
inclusion criteria: * willing to work with a health coach * plans to reside in alameda county for the next year * has a reliable phone number * speaks english or spanish * 18 years of age or older * meets at least one of the following three criteria: (1) low medication adherence defined as a continuous medication gap of at least 1 month in the past year or a new diagnosis of diabetes and/or hypertension; (2) no patient-identified primary care provider (pcp) or no visit to pcp in 1 year; (3) one or more visits to the ed in the last 6 months. exclusion criteria: * life-expectancy less than 1 year * poorly controlled psychiatric illness * homeless * active and frequent use of illicit substances * currently incarcerated * already enrolled in a program for patients with high rates of hospitalization and/or emergency department visits * unable to consent due to an unstable condition or serious emotional or neurologic condition * admitted or anticipated to be admitted to the hospital from the ed

Keywords: community health workers community health workers: utilization emergency service primary health care/utilization health services accessibility
identifying inflammatory biomarkers of chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: chronic obstructive pulmonary disease (copd) is a condition that is characterized by airway obstruction due to inflammation. levels of inflammatory proteins may be linked to when and to what extent copd develops. this study will use data collected during the tucson epidemiological study of airway obstructive disease (tesaod) and its 33-year follow-up to determine the relationship between inflammatory protein expression and copd.

copd is a term that encompasses both chronic bronchitis and emphysema, two diseases that are characterized by airway obstruction that interferes with normal breathing. airway inflammation can stem from exposure to harmful fumes in the air, chronic bacterial infections in the airways, and a genetic predisposition to an inflammatory response to these agents. in people with copd, the airway inflammation may extend beyond the lungs and contribute to systemic symptoms and, ultimately, to an increased mortality risk. markers of systemic inflammation have been identified, but the relationship between these markers and when and to what extent copd develops has not been determined. this study will use data collected during the tesaod and its 33-year follow-up to determine the relationship between copd and the expression of various inflammatory proteins, including pro-inflammatory cytokines (e.g., il-6, il-8, tnf-alpha) and acute phase proteins (e.g., c-reactive protein, soluble cd14). this study will not recruit any new participants. detailed respiratory phenotypic information and serum samples that were collected during the tesaod study will be evaluated in conjunction with newly generated biomarker and protein information. no new phenotypic data or biological specimens will be collected in this study.

Eligibility criteria:
inclusion criteria: * enrolled in the tucson epidemiological study of airway obstructive disease (tesaod)

Keywords: copd emphysema chronic bronchitis inflammation cd14 tlr4 proteomics
french study in real life evaluating xybilun

Conditions: Erectile Dysfunction

Summary: collecting xybilun (viagra's generic) efficacity, tolerance, convenience and patients/doctors satisfaction's data at different doses (50-75-100 mg), is the aim of the study.

study design population patients without prior treatment with a first xybilun prescription patients already treated for who the treatment is remplaced by xybilun study perimeter 400 patients 50 investigators (sexologists, urologists)

Eligibility criteria:
inclusion criteria: * age \> or equal 18 years * erectile dysfunction at v1 light (group 1), moderate (group 2), severe (group 3): iief-6 score between 6 and 25 (iief-6 questions 1-5 and question 15) * more than 3 sexual intercourse * first prescription of xybilun (gr 1,2,3) or subtitution (gr 4) * information and non-opposition exclusion criteria: * sildénafil hypersensitivity * treatment with nitrogen oxide or guanylate cyclase * patient with sexual intercourse prohibited * noiana * alpha-blocker during past 3 months * norvir * participation in an other clinical trial * patient unable to read properly an information sheet * patient under guardianship/curatorship

Keywords: erectil dysfunction sildenafil xybilun
optimizing resuscitation after cardiac arrest in the community

Conditions: Cardiopulmonary Arrest Outcome

Summary: resuscitative efforts have been shown to be unsuccessful in most cases of out-of-hospital cardiac arrest (ohca), and survivors who do recover cardiac function often sustain severe hypoxic brain damage. time to efficacious care is a primary determinant of disability-free survival. in the jerusalem district, only 9% of ohca patients present with ventricular tachycardia/ventricular fibrillation (vt/vf) as the primary rhythm, whereas 77% present with asystole; this seems primarily to be the result of long collapse-to-arrival times. nevertheless, overly zealous resuscitation is undertaken in a high proportion of arrests with a futile prognosis, leading to excessive costs. study hypotheses: 1. subpopulations for whom intervention is futile/counter-productive are identifiable 2. substantial waste of resources can be avoided 3. optimization of emergency medical services (ems) reorganization without adding resources is an achievable goal


Eligibility criteria:
inclusion criteria: * all victims of non-traumatic out-of hospital cardiopulmonary arrest (defined as the absence of either spontaneous respiration or palpable pulse or both) within the jerusalem district. exclusion criteria: * patients with do-not-resuscitate orders or an advance directive to that effect.

Keywords: resuscitation sudden death cardiopulmonary resuscitation emergency medical services termination of resuscitation ventricular fibrillation out-of-hospital cardiac arrest asystole medical futility withdrawing treatment transportation of patients health expenditures healthcare costs
light as an aid for recovery in psychiatric inpatients

Conditions: Mental Illness

Summary: the purpose of this pilot study is to evaluate wether a naturalistic indoor light environment can improve sleep and mood in psychiatric inpatients

setting: 17 bed inpatient ward at a university mental health hospital rooms: the dimensions of all 17 rooms are identical with 4,54m x 3,14m, ceiling height 3,15m, a window, a bed, a table, a chair and a bathroom 1,55m x 1,85m. assignment of interventions: after admission patients are invited to participate in the study. if the patients wish to participate they will go through eligibility screen, sign informed consent and fill out questionnaires on sleep, mood and well-being (-t1). the patients (now participants) are randomly allocated (t0) by sealed envelope technique and the envelope is brought to the staff office and opened by a staff member who then from the computer in the office programs the participant's room to either intervention or control. randomization: the investigators used random permuted blocks of varying and blinded block size. a third party person created the envelopes and arranged them in blocks. blinding: the outcome assessor and data analyst is blinded to allocation. trial participants and care providers are unblinded. participants may be replaced to another room for practical, clinical reasons. in this case, the intervention/control conditions will follow the patient. data management: all data will be entered in redcap and stored in a electronic online secured database at aarhus university. power estimation: alfa: 0.05. beta: 0.20. effect size: change of 4 points in psqi with a standard deviation estimated to 4. number of patients in each arm: 17 (x 2 = 34). number needed to be included accounting for discontinuation: 60 (estimated) statistics: the investigators will calculate intention-to-treat. other statistical analyses will include logistic regression for dichotomous outcome data, analysis of covariance for continuous outcome data, and survival analysis for time-to-event outcome data. interim-analyses during the data-collection period to stop trial if intervention produces larger than expected benefits or harm or if investigators find evidence of no important difference between experimental and control interventions.

Eligibility criteria:
inclusion criteria: * admission exclusion criteria: * inability to provide written consent * mania

Keywords: lighting inpatients recovery sleep
identifying most effective treatment strategies to control arterial hypertension in sub-saharan africa

Conditions: Arterial Hypertension

Summary: this study is to compare the effectiveness of three different antihypertensive treatment strategies for reaching a target blood pressure (clinic bp) of \ /=65years of age in hiv-positive and hiv-negative patients with uncomplicated arterial hypertension in rural tanzania and lesotho.


Eligibility criteria:
inclusion criteria: * hiv-positive and negative patients of african descent and black ethnicity with a documented uncomplicated, untreated arterial hypertension (blood pressure \>/=140/90 mmhg) diagnosed at one of the 2 study sites exclusion criteria: * current hospitalization for any reason * not of african descent * refusal of an hiv-test or indeterminate hiv test result * history of cardiovascular event in the last month (anginal pain, stroke, myocardial infarction or diagnosis by a doctor) * symptomatic arterial hypertension (blood pressure \>/=180/110 mmhg plus headache or chest pain) or acute cardiovascular event * acute disease, (e.g. fever \>37.5°c or other signs of acute concomitant infection; dyspnea/respiratory distress; acute pain) * clinical signs of hypertension-mediated organ damage (heart failure, bilateral pitting edema, bilateral crackles or pleural effusion, distended jugular veins, ischemic heart disease (anginal pain on exertion), signs of current ischemic/hemorrhagic stroke (hemiparesis, loss of consciousness) * pregnancy (test required for females 18-45years of age) * non-consenting or inability to come for follow-up visits * creatinine clearance \</=30ml/min by chronic kidney disease epidemiology formula (ck-epi) estimation and measurement with a point-of care creatinine from capillary blood

Keywords: antihypertensive treatment
a study to assess the ability of a crossover study design to detect the efficacy of pregabalin in post-traumatic neuropathic pain patients

Conditions: Nerve Pain

Summary: the purpose of this study is to assess whether a cross-over type study design in post-traumatic neuropathic patients can be used to assess the activity of potential analgesic agents

methodology study to evaluate a cross-over study design in post-traumatic neuropathic pain patients.

Eligibility criteria:
inclusion criteria: * patients require a diagnosis of post-traumatic peripheral neuropathic pain (nep), including post-surgical nep and nep due to peripheral nerve injury, which has lasted at least 3 months following the traumatic event. * patients during the screening week must have completed ≥ 4 daily pain scores and have an average daily pain score ≥ 4. * female patients of childbearing potential must have a negative urine pregnancy test at screening and be practicing an acceptable form of contraception. exclusion criteria: * patients with neuropathic pain (nep) that is not due to trauma; e.g. patients with trigeminal neuralgia, central pain, complex region pain syndrome type i, phantom limb pain, radiculopathy, painful diabetic neuropathy or post-herpetic neuralgia or patients with any other co-existing pain which cannot be differentiate from nep of peripheral origin. * patients who have previously failed to respond to pregabalin at a total daily dose of equal to or greater than 300 mg or are intolerant to those doses. * patients who have previously failed to respond to gabapentin at a total daily dose of equal to or greater than 1800 mg. * patients with any type or history of malignancy, except either where there has been no ongoing treatment for at least 6 months or all basal cell carcinomas; all patients with a history of brain or spinal tumors will be excluded. * patients who currently have ongoing litigation related to any injury affecting their pain symptomatology.
treatment of relapsed low-grade or follicular lymphoma with rituximab (also known as rituxan, idec-c2b8, idec-102)

Conditions: Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma

Summary: rituximab is an antibody made in a laboratory. it binds to lymphoma cells and kills them. treatment of recurrent b-cell lymphoma with rituximab may delay or prevent relapses. a total of 166 patients with recurrent b-cell lymphoma were given intravenous rituximab once a week for 4 weeks. the patients' tumors were measured before and after treatment. ten patients had a complete response and 70 patients had a partial response to rituximab. the median duration of response was 11.2 months.


Eligibility criteria:
inclusion criteria: * diagnosis of relapsed, low-grade or follicular b-cell lymphoma * cd20-positive lymphoma * progressive, measurable disease * sign informed consent * 3 weeks beyond standard therapy * good performance status * adequate hematologic, renal, and hepatic function exclusion criteria: * chronic lymphocytic leukemia * lesions greater than or equal to 10 cm in diameter * cns lymphoma * aids-related lymphoma * pleural effusions or ascites secondary to lymphoma * active, opportunistic infection * serious nonmalignant disease * prior investigational therapies, including prior anti-cd20 therapy * recent major surgery

Keywords: rituximab rituxan b-cell lymphoma low-grade follicular anti-cd20 monoclonal antibody
cetylpyridium chloride (cpc) based chewing gum and gingivitis

Conditions: Gingivitis; Plaque, Dental; Periodontal Diseases

Summary: this placebo-controlled, double-blinded, randomized crossover study evaluates the plaque and gingivitis reducing capacity of cetylpyridium chloride (cpc) chewing gum, with mechanical oral hygiene. the study will enroll 73 students, faculty, and staff from the uthealth school of dentistry. half of the eligible participants will be randomly assigned to get the cpc gum in the first treatment period (21 days), a wash-out period of 21 days, and then a placebo gum in the second treatment period (21 days). the other half will be assigned to follow the same schedule but with the treatment reversed. a statistician will perform the randomization. primary outcomes are assessed by validated tools, such as the plaque index (pi), gingival index (gi), and percent of bleeding sites on probe (bop).


Eligibility criteria:
inclusion criteria: * be aged 18 and older * be capable of giving informed consent themselves and are able and willing to participate in the study * patients willing to forgo any optional dental procedures during the study period, such as dental prophylaxis or teeth whitening * patients that regularly brush their teeth twice a day exclusion criteria: * pregnant or breastfeeding women * patients taking long-term anti-microbial or anti-inflammatory drugs * patients unable or unwilling to provide informed consent * self-reported use of tobacco products * gross oral pathology, including widespread caries or chronic neglect, extensive restoration, pre-existing gross plaque or calculus, or soft or hard tissue tumor of the oral cavity * less than 26 teeth in the mouth * orthodontic appliances or removable partial dentures that will compromise the ability of the potential subject to participate in the study * periodontitis as indicated periodontal pockets greater than 5 millimeters on more than one site * inability to comply with assigned treatment regimen

Keywords: cetylpyridium chloride (cpc) chewing gum
blood products transfusion in cardiac surgery after the implementation of a coagulation monitoring system at patient bedside: thromboelastometry versus standard transfusion protocol

Conditions: Hemostatic Disorders

Summary: main objective: determine whether by introducing thromboelastograph, the investigators reduced the number of packed red cells received by each patient (median) compared to the usual protocol, in which the indication for transfusion is based on laboratory tests: prothrombin time, time activated partial thromboplastin time, thrombin, reptilase, fibrinogen and platelet contage. design: prospective randomized controlled trial and single blinded. disease or disorder under study: study of coagulopathy in patients undergoing cardiac surgery with cardiopulmonary bypass (cpb). primary endpoint: median transfusion of packed red blood cells per patient. study population male and female patients over 18 years undergoing cardiac surgery with cardiopulmonary bypass to bleed excessively. duration of treatment: the coagulation monitoring methods tested are made from protamine administration to cec output if a) the patient bleeds diffusely, or b) from arrival in the unit if not satisfied critics a) bleed excessively drains and until the patient stops bleeding (debit drains \<a 150ml / h).


Eligibility criteria:
inclusion criteria: * male and female patients * over 18 years * undergoing cardiac surgery * with cardiopulmonary bypass * bleed excessively as it is not possible to predict in advance who will bleed, informed consent will be required for all patients over 18 who are to undergo cardiac surgery with cpb. will be randomized to either group 1. those patients with diffuse bleeding after protamine administration. and / or 2. they bleed excessively after surgery. are excessive bleeding criteria: the debit ≥ 300ml drains in the first hour; ≥ 250ml in the second hour or ≥ 150ml at any later time. consider that the patient is bleeding excessively when the drains debit is \<150ml. exclusion criteria: * patients \<18 years * extracorporeal circulation surgery * surgery with mini extracorporeal circulation (mecc) * refuse to participate in the study.

Keywords: hemostatic disorders ardiac surgery cardiopulmonary bypass